Cardiovascular GLP-1 indication approval 2026: Zepbound (tirzepatide)
49%YES chance
Yes
49%
No
51%
Now 49.0%
Resolution
Resolves to the first GLP-1 to win an additional cardiovascular indication from FDA in 2026.
Source: https://www.fda.gov/
Resolves by Apr 8, 2027.
Recent trades
- NO@tatumwalsh19.8 sh@ 49%10 SP
Top holders
YES holders
No holders yet.
NO holders
No holders yet.
News
Refreshed every 6 hours
No news yet. Endcap's news crawler refreshes every 6 hours.